Unichem Laboratories Reports Mixed Financial Results Amidst Rising Debt Concerns in June 2025

Unichem Laboratories has recently reported its financial results for the quarter ending June 2025, revealing a complex landscape for the small-cap pharmaceutical company. The evaluation changes indicate a notable shift in the company's score, which has seen a revision from 24 to -5 over the past three months.
On a positive note, Unichem Laboratories has achieved net sales of Rs 1,113.78 crore, reflecting a year-on-year growth of 21.72%. This suggests a favorable near-term sales trend, highlighting the company's ability to generate revenue despite the challenges faced.

Conversely, the financial results also reveal significant concerns. The profit before tax less other income (PBT) has reported a substantial decline, landing at Rs -15.84 crore, which is considerably lower than the average PBT of the previous four quarters. Similarly, the profit after tax (PAT) has also fallen sharply to Rs -10.47 crore, indicating a troubling trend in profitability. The operating profit margin has reached its lowest point in five quarters at 4.27%, suggesting a decline in operational efficiency.

Additionally, the company's debt-equity ratio has risen to 0.19 times, the highest in recent periods, indicating increased borrowings to support operations, which may impact liquidity.

For more insights on Unichem Laboratories and its financial performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.